Atypical Dopamine Responsive Parkinsonism in HIV Seroconversion
Objective: To add to the current body of knowledge of the association of HIV infection and dopamine responsive parkinsonism. Background: South Africa has one of…Striatal FP-CIT SPECT findings for progressive supranuclear palsy subtypes
Objective: In our previous study FP-CIT SPECT (FP-CIT) in progressive supranuclear palsy-Parkinsonism (PSP-P) revealed higher anterior striatal accumulation, and PSP- Richardson’s syndrome (PSP-RS) revealed lower…Opposite effects of dopamine on specific NoGo perfomance in young and late onset Parkinson’s disease and the relationship to nigrostriatal degeneration
Objective: To investigate inhibitory control under dopamine (DA) in Parkinson’s disease (PD). Background: The pattern of degeneration in PD as well as side effects of…A unique case of DAT positive Parkinson’s disease along with a mutable Huntington’s gene
Objective: The aim of this abstract is to report a unique case of DAT positive Parkinson’s disease with a mutable Huntington’s gene. Background: Huntington’s disease…A neuroimaging-based model for disease progression in Parkinson’s disease
Objective: We model the rate of disease progression over 4 years in subjects with Parkinson’s disease based on neuroimaging features acquired at baseline. Background: DaTSCAN…Profound reduction of DAT-SPECT signal in multiple system atrophy (MSA)
Objective: To evaluate the extent of degeneration in dopamine nerve terminal in striatum in the patients with MSA-P and MSA-C, and to compare the progression…Utility of DaTscan Imaging in Differentiating Drug Induced Parkinsonism from IPD and Other Forms of Parkinsonism
Objective: To determine clinical correlates which differentiate drug induced Parkinsonism (DIP) from IPD and other forms of Parkinsonism using DaT-SPECT imaging. Background: DaT-SPECT imaging is…Semiquantitative analyses of DAT-SPECT imaging with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism
Objective: We investigate the usefulness Dopamine transporter (DAT)-SPECT with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism. Background: DAT-SPECT imaging is sensitive…Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium
Objective: A key goal of the Critical Path for Parkinson’s Consortium (CPP) is to qualify, with regulatory agencies, drug development tools for use in PD…Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Objective: To assess the neurobiological substrate of initial cognitive decline in Parkinson’s disease (PD) to inform patient management, clinical trial design, and development of treatments.…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 16
- Next Page »